Pages that link to "Q54440265"
Jump to navigation
Jump to search
The following pages link to In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. (Q54440265):
Displaying 50 items.
- New treatment options against gram-negative organisms (Q21194906) (← links)
- In vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model. (Q33622755) (← links)
- Ceftaroline fosamil: drug profile and clinical data (Q33772804) (← links)
- Ceftaroline fosamil: a brief clinical review (Q33939080) (← links)
- Ceftaroline: a cephalosporin with expanded Gram-positive activity (Q34016030) (← links)
- Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. (Q34017518) (← links)
- In vitro activity of new cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008-2011. (Q34363461) (← links)
- In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates (Q34483441) (← links)
- Acinetobacter baumannii: emergence of a successful pathogen (Q34795807) (← links)
- In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. (Q35004919) (← links)
- Current and novel antibiotics against resistant Gram-positive bacteria (Q35026521) (← links)
- Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. (Q35065778) (← links)
- In Vivo Efficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae (Q35065798) (← links)
- Ceftaroline: A New Cephalosporin with Activity Against Methicillin-Resistant Staphylococcus aureus (MRSA) (Q35117981) (← links)
- Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia (Q35408518) (← links)
- Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit (Q35427862) (← links)
- Ceftaroline in complicated skin and skin-structure infections (Q35715381) (← links)
- In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme (Q35822261) (← links)
- In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase (Q35960745) (← links)
- Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus (Q36482771) (← links)
- Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. (Q37071199) (← links)
- In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study (Q37263425) (← links)
- Current challenges in treating MRSA: what are the options? (Q37291338) (← links)
- Emergence and management of drug-resistant enterococcal infections (Q37291346) (← links)
- Activity of ceftaroline against Enterococcus faecium PBP5. (Q37335869) (← links)
- Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge. (Q37392891) (← links)
- Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update (Q37514259) (← links)
- Newer developments in the treatment of Gram-positive infections (Q37636151) (← links)
- Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens (Q37718228) (← links)
- Ceftaroline for complicated skin and skin-structure infections. (Q37733561) (← links)
- Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options (Q37752231) (← links)
- Emerging drugs for complicated skin and skin-structure infections (Q37765900) (← links)
- Resistant pathogen-associated skin and skin-structure infections: antibiotic options (Q37785546) (← links)
- Ceftaroline: a new broad-spectrum cephalosporin (Q37850216) (← links)
- Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus (Q37861942) (← links)
- What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia? (Q37863946) (← links)
- Will new antimicrobials overcome resistance among Gram-negatives? (Q37942654) (← links)
- Ceftaroline Fosamil: A Novel Broad-Spectrum Cephalosporin with Activity Against Methicillin-Resistant Staphylococcus aureus (Q37947221) (← links)
- Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections (Q38006689) (← links)
- Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection (Q38010783) (← links)
- Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections (Q38025132) (← links)
- In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). (Q38035808) (← links)
- Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. (Q38061168) (← links)
- New β-lactam-β-lactamase inhibitor combinations in clinical development (Q38076455) (← links)
- Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on. (Q38115356) (← links)
- Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia (Q38117077) (← links)
- β-lactams against emerging 'superbugs': progress and pitfalls (Q38177344) (← links)
- Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections (Q38185097) (← links)
- Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil (Q38262950) (← links)
- Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint (Q38578638) (← links)